Isabella Ciccone, MPH

The POLARIS program includes 3 ongoing phase 1/2 clinical trials investigating the efficacy and safety of investigational gene therapy EXT101 in patients with SCN1A postive Dravet syndrome.

The founder and CEO at the Hereditary Neuropathy Foundation discussed how learning about patient experiences has influenced research in Charcot-Marie-Tooth disease. [WATCH TIME: 5 minutes]

Experts discussed new biomarker data from a phase 1/2 study, presented at the 2026 MDA Conference, of the gene therapy SGT-003 in boys living with Duchenne muscular dystrophy.

The 2026 MDA National Ambassador discussed the importance of connecting patients’ experiences with scientific understanding, as well as fostering a sense of community among those living with neuromuscular disease. [WATCH TIME: 2 minutes]

New data from the pivotal study of investigational therapy zilganersen in Alexander disease will be presented at the 2026 American Academy of Neurology (AAN) annual meeting in Chicago.

Here's some of what is coming soon to NeurologyLive® this week.

A new retrospective analysis presented at AD/PD 2026 showed that cutaneous phosphorylated α-synuclein testing reduced diagnostic and management-related health care expenditures.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending March 20, 2026.

Sleep medicine specialist Karin Johnson, MD, FAAN, FAASM, shared the main takeaways from a recently published guideline on evaluating and managing obstructive sleep apnea in hospitalized adults.

Levacetylleucine met its primary end point in a phase 3 trial of patients living with ataxia-telangiectasia, with no drug-related serious adverse events reported, supporting the sNDA.

An analysis of baseline data from the phase 2b LUMA study suggested that keystroke dynamics captured through a smartphone-based typing task could provide a reliable method for assessing disease progression in Parkinson disease.

The research portfolio director at the Muscular Dystrophy Association highlighted the collaborative spirit, the expanding therapeutic pipeline, and the growing emphasis on patients’ voices in neuromuscular disease on display at MDA 2026. [WATCH TIME: 8 minutes]

The child neurologist at Children’s Hospital of Philadelphia discussed the real-world safety data of givinostat use in patients with Duchenne muscular dystrophy at the 2026 MDA Conference. [WATCH TIME: 5 minutes]

Since paraneoplastic neurologic syndromes remain underrecognized in oncology, experts recently discussed diagnostic challenges, treatment strategies, and the need for clinical vigilance.

A phase 1/2 study aims to assess the safety and tolerability of nivudirsen, also known as BMN 351, in single ascending and multiple ascending doses among patients living with Duchenne.

A neurologist at Georgetown University, MedStar Health, discussed phase 2/3 data presented at the 2026 MDA Conference that supports efgartigimod as a novel treatment for inflammatory myopathies. [WATCH TIME: 2 minutes]

Here's some of what is coming soon to NeurologyLive® this week.

A retrospective cohort study reported that myocardial fibrosis detected by cardiac MRI was associated with higher fatigue scores among women carriers of Duchenne or Becker muscular dystrophy.

At the 2026 MDA Conference, a neurologist at Nemours Children's Hospital discussed practical strategies for navigating insurance to ensure patients can access newly available neuromuscular therapies. [WATCH TIME: 3 minutes]

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending March 13, 2026.

The professor of neurology at Columbia University Irving Medical Center highlighted the decades of research collaboration for patients with neuromuscular disease at the 2026 MDA conference.

The study design of the phase 3 STELLAR trials, presented at the 2026 MDA Conference, aims to investigate salanersen among presymptomatic infants with spinal muscular atrophy.

Here's some of what is coming soon to NeurologyLive® this week.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending March 6, 2026.

Neuro-oncology experts examined how emerging cancer therapies may reshape the spectrum of paraneoplastic neurologic syndromes. [WATCH TIME: 4 minutes]

Catch up on any of the neurology headlines you may have missed in February 2026, compiled into 1 place by the NeurologyLive® team.

A new study showed that higher baseline Epworth Sleepiness Scale scores were associated with greater early continuous positive airway pressure adherence in patients with obstructive sleep apnea.

Neuro-oncology experts discussed best practices for initiating immunomodulatory therapy in patients with PNS, factors influencing neurologic recovery, and the role of early specialty involvement and supportive care in optimizing long-term outcomes. [WATCH TIME: 4 minutes]

Full data from the FENhance studies of fenebrutinib will be presented at the 2026 American Academy of Neurology Annual Meeting and submitted for regulatory review along with FENtrepid data in multiple sclerosis.

Neuro-oncology experts examined how cumulative neurotoxicity from cytotoxic and targeted therapies can obscure paraneoplastic neurologic syndromes, and how treatment timing and modification decisions influence neurologic outcomes. [WATCH TIME: 6 minutes]